Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Guardant Health, Inc. (NASDAQ:GH ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-CEO AmirAli Talasaz - Co-CEO Michael Bell - CFO Conference Call Participants Tejas Savant - Morgan Stanley Dan Arias - Stifel Mark Massaro - BTIG Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Jack Meehan - Nephron Research Dan Brennan - TD Cowen Patrick Donnelly - Citi Derik De Bruin - Bank of America Operator Hello, everyone, and welcome to the Guardant Health Q3 2023 Earnings Call. My name is Thrisha, and I'll be your operator today.

Guardant Health, Inc. (GH) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health (GH) Reports Q3 Earnings: What Key Metrics Have to Say

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 Reported 43,900 tests to clinical customers and.

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences: Jefferies 14th Annual Global Healthcare Conference in London, UK Presentation on Thursday, November 16 at 9:00 a.m. Greenwich Mean Time Piper Sandler 35th Annual Healthcare Conference in New York, NY Fireside Chat on Tuesday, November 28 at 9:30 a.m. Eastern Time Interested parties may access live and ar.

Guardant Health to Participate in Upcoming November Investor Conferences

PALO ALTO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between research and care, today announced an initiative to integrate Guardant's comprehensive genomic profiling tests within Flatiron's OncoEMR®, a leading cloud-based electronic medical record (EMR) tool. The integrati.

Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer. Results from the trial, which is an ISS study sponsored by IFOM ETS – the AIRC Institut.

First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.

Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Guardant Health's various products are all designed to help physicians and patients fight cancer. The company's revenue growth has been good, but its net losses are helping drag down the stock.

1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years

Exact Sciences

Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences' shares are up more than 31% so far this year, while Guardant is up a little more than 5%.

Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?

Guardant Health (GH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Guardant Health (GH) Surges 8.8%: Is This an Indication of Further Gains?

Analysts at both Bernstein and Piper Sandler had good things to say about Guardant Health this week. Shares of the precision oncology company had plunged more than 35% in September despite a lack of company-specific news.

Why Guardant Health Stock Jumped 15% This Week

Guardant Health stock has lost half its value over the past year. That's the bad news.

Why Guardant Health Stock Popped Again Today

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy or surveillance. It is.

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable (inoperable) advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy for treatment with ENHERTU® (trastuzumab deruxtecan). ENHERTU.

Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in patients with stage II colon cancer after curative-intent surgery with a planned final readout in 2026. “Our MRD test has great potential to help patients and their doctors.

Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York. Guardant Health's management is scheduled to participate in a fireside chat on Monday, September 11, at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors.

Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Guardant Health (GH) Could Rally 42.09%: Here's is How to Trade

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY starting at 8:00 a.m. Eastern time / 5:00 a.m. Pacific Time. The event will feature presentations by several members of the company's leadership team. Interested parti.

Guardant Health to Host Investor Day on September 7, 2023

Pinterest

Guardant Health's fight against cancer is also proving to be profitable for the company. Pinterest is looking to benefit from e-commerce in addition to its advertising business.

2 Cathie Wood Stocks to Buy and Hold for 10 Years

Guardant Health, Inc. (NASDAQ:GH ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Michael Bell - CFO Conference Call Participants Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Patrick Donnelly - Citigroup David Delahunt - Goldman Sachs Group Daniel Leonard - Crédit Suisse Andrew Brackmann - William Blair & Company Sung Ji Nam - Scotiabank Operator Hello, everyone, and welcome to the Guardant Health Second Quarter 2023 Earnings Call. My name is Emily, and I'll be coordinating your call today.

Guardant Health, Inc. (GH) Q2 2023 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights Revenue of $137.2 million for the second quarter of 2023, an increase of 26% over the second quarter of 2022 Reported 43,500 tests to clinical customers and 6,.

Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance

Illumina

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies' long-term, commercial partnership. The three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, includ.

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal™ molecular residual disease (MRD) test. Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after treatment, including surgery, to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy o.

Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana

The mean of analysts' price targets for Guardant Health (GH) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Guardant Health (GH) Have the Potential to Rally 39.77% as Wall Street Analysts Expect?

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com.

News for Guardant Health Inc Stock (GH)